Cue Biopharma (NASDAQ:CUE) Issues Quarterly Earnings Results

Cue Biopharma (NASDAQ:CUE) issued its quarterly earnings results on Friday. The company reported ($24.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45), FiscalAI reports. Cue Biopharma had a negative return on equity of 98.30% and a negative net margin of 59.65%.The business had revenue of $7.88 million for the quarter, compared to analysts’ expectations of $3.00 million.

Cue Biopharma Price Performance

NASDAQ:CUE traded up $3.12 during midday trading on Friday, hitting $34.20. The company’s stock had a trading volume of 157,074 shares, compared to its average volume of 195,652. Cue Biopharma has a fifty-two week low of $4.97 and a fifty-two week high of $45.50. The firm has a market cap of $143.64 million, a P/E ratio of -6.12 and a beta of 2.47. The firm’s 50 day moving average is $29.50 and its 200-day moving average is $147.28.

Insider Buying and Selling

In other news, CEO Shao-Lee Lin sold 18,258 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $28.62, for a total value of $522,543.96. Following the sale, the chief executive officer directly owned 705,995 shares of the company’s stock, valued at $20,205,576.90. This represents a 2.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 14.56% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. lifted its position in Cue Biopharma by 730.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after purchasing an additional 73,000 shares during the period. Squarepoint Ops LLC acquired a new stake in Cue Biopharma during the 3rd quarter worth about $62,000. Stifel Financial Corp raised its stake in shares of Cue Biopharma by 25.4% during the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after buying an additional 50,000 shares during the last quarter. Finally, Boothbay Fund Management LLC purchased a new position in shares of Cue Biopharma during the 3rd quarter valued at about $439,000. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Weiss Ratings upgraded shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Wall Street Zen upgraded shares of Cue Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.